Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Combine operations research with molecular biology to stretch pharmacogenomics and personalized medicine-A case study on HIV/AIDS

Full text
Author(s):
Joly, Marcel [1, 2, 3] ; Pinto, Jose M. [2, 4] ; Rondo, Patricia H. C. [1] ; Rodrigues, Rosangela [5] ; Ferreira, Joao L. P. [5] ; Cavalcanti, Jaqueline S. [5] ; Brigido, Luis F. M. [5] ; Odloak, Darci [2]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Sch Publ Hlth, BR-01246904 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Dept Chem Engn, BR-05508970 Sao Paulo, SP - Brazil
[3] Petrobras Petr Brasileiro SA, Ctr Excellence Appl Ind Automat Technol, BR-05508970 Sao Paulo, SP - Brazil
[4] Polytech Univ, Othmer Jacobs Dept Chem & Biol Engn, Metrotech Ctr 6, Brooklyn, NY 11201 - USA
[5] Adolfo Lutz Inst Sao Paulo, Virol Ctr, Retrovirus Lab, BR-01246902 Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Computers & Chemical Engineering; v. 80, p. 114-129, SEP 2 2015.
Web of Science Citations: 4
Abstract

The dramatic reduction in morbidity and mortality associated with the use of highly active antiretroviral therapy has created new challenges for clinicians: AIDS has become a chronic, potentially life-threatening, condition in many clinical instances. In this paper, a novel system engineering approach based on mixed-integer linear programming (MILP) is presented to support HIV/AIDS clinicians when formulating real-world therapeutic plans for heavily treatment-experienced patients under variable settings. Our results suggest that, while current practices (standard protocols and/or subjective recommendations based on the clinician's experience) can generally provide satisfactory management of drug resistance in the short-term, optimization-based therapy planning has a far greater potential to achieve this goal over expanded time horizons thereby changing paradigms and rethinking best practices in the HIV/AIDS clinical arena. Moreover, the ability of this methodology to address other viral pathologies (e.g., hepatitis B and C virus) can make this work appeal to a broader audience. (C) 2015 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 11/21958-2 - Genetic resistance to HIV-1 in the salvage therapy with new antiretroviral drug classes
Grantee:Luís Fernando de Macedo Brígido
Support Opportunities: Regular Research Grants